Neurosoft Bioelectronics raises $7.5M for scalable brain-computer interfaces

Neurosoft Bioelectronics, a neurotechnology company developing scalable and minimally invasive brain-computer interfaces (BCIs), has raised $7.5 million in an oversubscribed seed funding round led by Skybound Venture Capital, with participation from Protocol Labs, IAG Capital Partners and Connecticut Innovations, among others. The latest financing brings the company’s total funding to more than $20 million.

Headquartered in Switzerland with operations in New York, Neurosoft Bioelectronics is developing a platform designed to provide access to the full cortex without penetrating brain tissue. Its proprietary soft and stretchable electrodes are significantly more compliant than conventional neural interfaces and are intended to support broader cortical coverage through minimally invasive procedures.

The company says its long-term objective is to build a large-scale neural data platform capable of supporting foundation models of the human cortex. According to Neurosoft, data collected through its implantable devices could help improve the performance of both invasive and non-invasive brain-computer interfaces over time.

Nicolas Vachicouras, PhD, said the company’s soft electrode technology and regulatory approach enable Neurosoft to collect neural data at a scale and quality that is difficult to achieve safely with existing alternatives, adding:

That data is the foundation for improved clinical outcomes, and a cortical foundation model that will help shape the next generation of brain interfaces. The investor support we’ve seen in this round validates that we’re on the right path.

To date, Neurosoft has tested its technology in 10 patients across two ongoing clinical trials at UTHealth Houston and UMC Utrecht, including a 64-channel soft brain interface study for epilepsy surgery guidance. The company says its technology portfolio includes more than 25 patents and over 25 peer-reviewed scientific publications.

With the new funding, Neurosoft Bioelectronics plans to advance its clinical and commercial milestones, including demonstrating minimally invasive deployment in human patients and progressing toward US commercialisation of its first brain interface product.